All In Biotech

Drug Trial Radar · NCT05574010

A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

A Phase 1B Open-label/Phase 2 Double-blind Placebo- Controlled Study for Pharmacodynamic (PD) Activity, Pharmacokinetics (PK), Safety, and Tolerability of KAN-101 In Patients With Celiac Disease (CeD)

Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 128 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

128

Actual

Start

Nov 15, 2022

Primary completion

Nov 29, 2024

Study completion May 19, 2025

Sponsor

Sponsor type
Industry
Collaborators
Pfizer
First posted
Oct 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the Pharmacodynamic (PD), safety, tolerability, Pharmacokinetic (PK), and plasma biomarker response of KAN-101 in participants with Celiac Disease (CeD).

Conditions

  • Celiac Disease

Interventions

  • Cohort 1 in Part ADrug

    Dose 1 KAN-101 Intravenous (IV) infusion

  • Cohort 2 in Part ADrug

    Dose 2 KAN-101 Intravenous (IV) infusion

  • Placebo: Group 1 in Part B and Part COther

    Placebo Intravenous (IV) infusion

  • Group 2 in Part B and Part CDrug

    Dose 3 KAN-101 Intravenous (IV) infusion

  • Group 3 in Part B and Part CDrug

    Dose 4 KAN-101 Intravenous (IV) infusion

  • Group 4 in Part B and Part CDrug

    Dose 5 KAN-101 Intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and Severity of TEAEs as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) in Part ATime frame: From screening until the safety follow-up visit on Day 28
  2. Change in Pre- and Post-Gluten Challenge (GC) IL-2 Response From Baseline to Day 15Time frame: From Baseline screening to Day 15
  3. Change in IL-2 Response From Day 15 Pre-GC to Day 15 Post GCTime frame: 0 (pre-GC) and 4 hours post-GC on Day 15

Locations

36 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Anaheim Clinical Trials, LLC

    Anaheim, California

  • GCP Research

    St. Petersburg, Florida

  • Agile Clinical Research Trials

    Sandy Springs, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • Sneeze, Wheeze & Itch Associates, LLC

    Normal, Illinois

  • Indiana University Health University Hospital

    Indianapolis, Indiana

  • University of Iowa

    Iowa City, Iowa

  • Mayo Clinic

    Rochester, Minnesota

  • Prism Research LLC dba Nucleus Network

    Saint Paul, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Quality Clinical Research

    Omaha, Nebraska

  • Celiac Disease Center at Columbia University

    New York, New York

  • North Carolina Clinical Research

    Raleigh, North Carolina

  • Aventiv Research, Inc. d/b/a Centricity Research

    Columbus, Ohio

  • Great Lakes Gastroenterology Research, LLC

    Mentor, Ohio

  • Northshore Gastroenterology Research, LLC

    Westlake, Ohio

  • Penn State Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • The University of Texas Health Science Center at Houston

    Houston, Texas

  • Digestive Research of Central Texas

    Waco, Texas

  • Advanced Research Institute

    Ogden, Utah

  • Velocity Clinical Research, Salt Lake City

    West Jordan, Utah

  • Campbelltown Hospital

    Campbelltown, New South Wales, Australia

  • Wesley Research Institute

    Auchenflower, Queensland, Australia

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Box Hill Hospital

    Box Hill, Victoria, Australia

  • The Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • St John of God Midland Public and Private Hospitals

    Midland, Western Australia, Australia

  • Optimal Clinical Trials

    Auckland, Auckland, New Zealand

  • PCRN Trials

    Takapuna, Auckland, New Zealand

  • P3 Research - Tauranga

    Tauranga, Bay of Plenty, New Zealand

  • Waikato Hospital

    Hamilton, Hamilton, New Zealand

  • P3 Research - Dunedin

    Dunedin, Otago, New Zealand

  • P3 Research - Palmerston North

    Paraparaumu, Wellington Region, New Zealand

  • P3 Research - Wellington

    Wellington, Wellington Region, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.